TRPC5 and peripheral arterial disease: For instance, pre-clinical trials already showed that stimulating TRPC5 with riluzole could represent a promising strategy to treat PAD, while the intra-myocardial/coronary injection of P3HT nanoparticles coupled to optical pacing of the heart could stimulate circulating ECFCs to rescue coronary circulation upon TRPV1 activation.